24
January 2025
IXICO plc
("IXICO" or the
"Company")
Results of
AGM
IXICO plc (AIM: IXI), the medical imaging
advanced analytics company delivering insights in
neuroscience announces that all resolutions
put forward to its Annual General Meeting held earlier today were
duly passed and the votes cast were as follows:
|
|
RESOLUTION
|
VOTES
FOR
|
%
|
VOTES
AGAINST
|
%
|
VOTES
TOTAL
|
% ISC VOTED
|
VOTES
WITHHELD
|
|
1
|
Reports and Accounts
|
68,485,623
|
99.95%
|
31,468
|
0.05%
|
68,517,091
|
73.94
|
400
|
|
2a
|
Election of Bram Goorden
|
68,473,140
|
99.95%
|
32,668
|
0.05%
|
68,505,808
|
73.93
|
11,683
|
|
2b
|
Re-election of Grant Nash
|
68,474,566
|
99.95%
|
36,376
|
0.05%
|
68,510,942
|
73.93
|
6,549
|
|
2c
|
Re-election of Mark Warne
|
68,473,966
|
99.95%
|
36,976
|
0.05%
|
68,510,942
|
73.93
|
6,549
|
|
2d
|
Re-election of Dr Dipti
Amin
|
68,470,760
|
99.95%
|
35,048
|
0.05%
|
68,505,808
|
73.93
|
11,683
|
|
2e
|
Re-election of Kate Rogers
|
68,475,894
|
99.95%
|
35,048
|
0.05%
|
68,510,942
|
73.93
|
6,549
|
|
3
|
Re-appointment of
Moore Kingston Smith
Auditors
|
68,473,359
|
99.95%
|
36,401
|
0.05%
|
68,509,760
|
73.93
|
7,731
|
|
4
|
Allotment of Securities
|
68,475,089
|
99.94%
|
41,502
|
0.06%
|
68,516,591
|
73.94
|
900
|
|
5
|
* Disapply Pre-Emption
Provisions
|
68,399,849
|
99.83%
|
116,742
|
0.17%
|
68,516,591
|
73.94
|
900
|
|
6
|
* Issue of
'value multiple and exit' share options to Bram Goorden, CEO, and
Grant Nash, CFO.
|
68,352,128
|
99.76%
|
163,273
|
0.24%
|
68,515,401
|
73.94
|
2,090
|
|
7
|
* To adopt
new Articles of Association for the Company
|
68,473,361
|
99.94%
|
43,830
|
0.06%
|
68,517,191
|
73.94
|
300
|
* Special
Resolutions
Please note that a 'vote withheld'
is not a vote under English Law and is not counted in the
calculation
of the proportion of the votes 'for'
and 'against' a resolution.
Further information:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets
Limited (Nominated Adviser
and
Sole Broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Nigel Birks/Harriet Ward (Corporate
Broking)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
| |
About
IXICO www.IXICO.com
IXICO is dedicated to delivering insights in
neuroscience to help transform the advancement of investigational
therapies for neurological diseases, such as Huntington's disease,
Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience by supporting pharmaceutical
companies across all phases of CNS clinical research. IXICO's goal
is to be a leading advocate of artificial intelligence in medical
image analysis.
IXICO has developed and deployed
breakthrough data analytics, at scale, through its remote access
technology platform, to improve the return on investment in drug
development and reduce risk and uncertainty in clinical trials for
the Company's pharmaceutical clients.
